COMMUNIQUÉS West-GlobeNewswire

Better Choice Company to Present at the 2024 ThinkEquity Conference and Provides Detail on Sales in China and the Acquisition of SRx Health
26/09/2024
Sustained Sales Momentum in China in Q3 Following 37% Sequential Growth in Q2 Acquisition of SRx Health Remains On-Track TAMPA, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice [...]
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
26/09/2024
TARRYTOWN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its third quarter 2024 financial and operating results on Thursday, October 31, [...]
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
26/09/2024
SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine [...]
Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET
26/09/2024
New Istaroxime Phase 2b clinical results to be presented by Windtree and top cardiology expert Review of cardiogenic shock and other programs, including Windtree’s strategy and planned near-term milestones WARRINGTON, [...]
QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays
26/09/2024
Product line earns CE-marking under new EU IVDR framework – including QIAstat-Dx Analyzer, QIAstat-Dx Rise and panels for detection of gastrointestinal and respiratory infections // Certification confirms that QIAGEN’s [...]
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
26/09/2024
TORONTO and HAIFA, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing exosome-based [...]
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
26/09/2024
Company to host conference call today at 4:30 p.m. ET SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced a voluntary pause of enrollment in the Phase 3 HARMONY Study [...]
Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
26/09/2024
CAMBRIDGE, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that its stockholders voted to approve [...]
Clover Health Appoints Seasoned Healthcare Executive as Chief Operating Officer for Medicare Advantage Operations
26/09/2024
New Jersey Native Joseph Brand to Lead Operational Efficiency and Innovation in MA Operations, Enhancing Care for Physicians and Patients FRANKLIN, Tenn., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, [...]
Grant of Restricted Stock Units and Warrants to Employees in Genmab
26/09/2024
Company Announcement COPENHAGEN, Denmark; September 26, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 23,954 restricted stock units and 13,915 warrants to employees of the Company and [...]
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
26/09/2024
REDWOOD CITY, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent [...]
Corza Medical remporte le Prix d’excellence mondial 2024 du fabricant de solutions de suture de plaies le plus innovant
26/09/2024
WESTWOOD, Massachusetts, 26 sept. 2024 (GLOBE NEWSWIRE) -- Corza Medical (« Corza » ou la « Société »), une entreprise de technologie médicale de premier rang à l’échelle mondiale, proposant des services remarquables, [...]
Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome
26/09/2024
MNV-201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria In pre-clinical studies, MNV-201 demonstrated improved engraftment and bone marrow [...]
Culture Biosciences Appoints Chris Williams as Chief Executive Officer
26/09/2024
Former COO of Cytek Biosciences brings extensive bioprocessing experience to drive next phase of growth at Culture Biosciences South San Francisco, CA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Culture Biosciences, a leader in [...]
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update
26/09/2024
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update Financial and business highlights Total H1 2024 incomes of €82.5 million thanks to Company’s new partnerships. New strategic [...]
OSE Immunotherapeutics annonce des résultats semestriels 2024 remarquables et fait le point sur ses avancées
26/09/2024
OSE Immunotherapeutics annonce des résultats semestriels 2024 remarquables et fait le point sur ses avancées Éléments financiers et business développement Revenus du premier semestre 2024 de 82,5 millions d’euros grâce [...]
Vistin Pharma ASA: Mandatory notification of trade
26/09/2024
Saga Pure ASA has on 26 September 2024 purchased 50,000 shares in Vistin Pharma ASA at NOK 28.2 per share. After the transaction Saga Pure ASA has a holding of 700,000 shares, corresponding to 1.58% ownership.Saga Pure [...]
Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines
26/09/2024
First award under UNICEF emergency tender to secure availability of mpox vaccines for Africa COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced an agreement with UNICEF for the [...]
Bavarian Nordic Upgrades its Financial Guidance for 2024
26/09/2024
COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) upgrades its financial guidance for 2024. Based on today’s announced mpox vaccine order and additional orders secured, combined with improved [...]

Pages